Profitable fast growing national traffic businesses with bases in WA, SA & Victoria

Melbourne: Traffic signage and street sweeping company The Traffic Group (ASX:TTG) opened its initial public offer (IPO) on 28-10-2009 to raise $5 million. The company is profitable and plans to substantially expand by winning new business, acquiring new businesses and to buy assets from distressed competitors.

The Traffic Group was established in 2007 by managing director Con Scrinis. The strategy of The Traffic Group is to consolidate the fragmented traffic services industry and the IPO fundraising will accelerate the company’s growth. Read more…

Viewed 20156 times by 533 viewers

Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to announce a major New South Wales hospital has been named as a second site to trial a novel late stage anti-cancer therapy using a common cold virus to target and attack tumours.

Sydney’s St George Hospital will begin Phase I trials of intravenous virotherapy using the trademarked virus CAVATAKTM, in collaboration with the anti-cancer therapeutics company, Viralytics.

Leading oncologist, Dr Winston Liauw, from Sydney’s St George Hospital said patients were being recruited from the greater Sydney metropolitan area and he was enthusiastic about the study.

“This is a novel treatment approach to late stage cancer that holds great promise. Starting our collaboration with Viralytics at Phase I of the development means we can contribute significantly to the knowledge and success of the CAVATAKTM product” Read more…

Viewed 3887 times by 343 viewers

Former West Australian Premier Alan Carpenter has been appointed to a senior management role at Wesfarmers Limited.

Mr Carpenter will take up the position of Executive General Manager, Corporate Affairs in early December.
Wesfarmers Managing Director Richard Goyder said he was delighted Mr Carpenter had decided to join the company.
“Alan is a very talented person who, as a senior Minister and Premier, made a significant contribution to Western Australian public life,” he said.

“I am looking forward very much to working with him in the post-politics phase of his career. Read more…

Viewed 4644 times by 379 viewers

The Board of Tandou has today recommended that shareholders REJECT the unsolicited proportional takeover offer from GPG of 30 cents per share for up to 50% of each shareholder’s shares (Proportional Offer).

Tandou’s Directors have unanimously recommended the rejection, concluding that GPG’s Proportional Offer is priced significantly below their view of the underlying fundamental value of Tandou shares of between $0.64 and $0.68 per share. Furthermore, given the offer is for only half of each Tandou shareholder’s shares, the Board believes the structure of the Proportional Offer is unattractive.

As previously announced, Tandou’s largest shareholder, Volcot Holding Ag (30.59%) has advised that it will not accept GPG’s Proportional Offer at 30 cents per share. Read more…

Viewed 2848 times by 388 viewers

Cytopia Limited (ASX: CYT) has received ethics committee approval to commence dosing patients in its CYT997 Phase II clinical trial in glioblastoma multiforme (GBM) at the Gold Coast Hospital in Southport, Queensland. The Gold Coast Hospital will be the company’s fourth clinical site for this study. Dr Andrew Hill will act as local Principal Investigator.

GBM is an aggressive form of brain tumour which is currently treated by surgical resection, and/or radiation and chemotherapy.  Despite these treatments, the condition recurs in most patients, leading to poor patient outcomes.  GBM tumours are highly vascular, rendering them potentially susceptible to destruction by an anti-vascular agent such as CYT997.

The company will also shortly file the requisite regulatory submissions to the Medicines andHealthcare Products Regulatory Agency (MHRA) to enable dosing at clinical centres in the United Kingdom and is considering further centres in North America.

“The addition of the Gold Coast Hospital strengthens this program,” said Mr Andrew Macdonald, CEO of Cytopia. “The company is looking forward to concluding the doseescalation portion of this study early next year.”

Resignation of Director

Cytopia announced today that Mr. Roderick Lyle, a non executive director of the Company will retire from the Cytopia Board with immediate effect, due to recent ill health.

Cytopia’s chairman, Mr. Bob Watson said “Since his appointment in 2005, Mr Lyle has made an excellent contribution to the Cytopia board, both as a director and as Chair of the Audit and Risk Committee. We are sorry to have lost Rod’s services and wish him a speedy recovery.”

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer. The lead program for the company is CYT997, a vascular disrupting agent for the treatmentof various cancers, and currently being trialled in Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter a Phase I/II clinical study in 2009.

On 6 October 2009, Cytopia announced a proposed merger with Toronto, Canada based YM BioSciences Inc. Details can be found at www.cytopia.com.au. It is expected that a Scheme Booklet, further explaining the basis for the merger, will be provided to Cytopia shareholders in November 2009.

For more information please contact:

Mr Andrew Macdonald

Chief Executive Officer

T: +61 3 9208 4232

E: andrew.macdonald@cytopia.com.au

Dr Gregg Smith

Director, Drug Development

T: +61 3 9208 4234

E: gregg.smith@cytopia.com.au

or, visit our website at: www.cytopia.com.au

Viewed 3592 times by 472 viewers

19 October 2009: Greenpower Energy Limited (ASX:GPP) has signed a Farm-In Agreement allowing Regal Resources Limited (ASX:RER) to establish an underground coal to liquids process at Greenpower’s Exploration Licence 4860. The area covers 154 km2 and is 10km from Traralgon.

A condition precedent is establishing the existence of a reserve of coal or carbonaceous material sufficient to support a commercial operation at the site. A further condition is successful renewal of Exploration Licence 4860, due to expire in August 2010.

Regal is currently planning to commence pilot testing its coal-to-liquids technology at Oak Park west of Melbourne. Assuming this is successful it will use this technology at the Gippsland site. Read more…

Viewed 4680 times by 428 viewers

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approves HalcyGen’s UK pharmacokinetic study to proceed

Tuesday 13th October 2009, Melbourne Australia: HalcyGen Pharmaceuticals Limited (ASX: HGN) has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin a pivotal pharmacokinetic study in the UK in order to progress its EU registration program for SUBA®-Itraconazole. The relevant independent research ethics committee also provided a favourable opinion on the study allowing HalcyGen to proceed immediately with recruitment and dosing of volunteers. SUBA®-Itraconazole is an improved generic formulation of the anti-fungal drug Sporanox®. Read more…

Viewed 3138 times by 340 viewers

Cytopia Limited (ASX:CYT) (”Cytopia”) has today announced that Cytopia and Toronto-based YM BioSciences Inc. (”YM”) have signed an exclusive and binding Implementation Agreement (“Agreement”) in which it is proposed that YM will acquire all of the issued shares and options in Cytopia. This transaction will be conducted by scheme(s) of arrangement (“Scheme(s)”) and shareholders (and optionholders if required)[i] are expected to vote on the Scheme(s) in January 2010.

Cytopia shareholders will be offered 1 YM share for every 11.737 Cytopia shares.[ii] Cytopia option holders will receive YM options at an equivalent ratio. The Share Scheme consideration represents a share price offer of $0.1659 per Cytopia share. This is a 58 % premium to the trading price of Cytopia shares on the ASX immediately prior to signing of the Agreement. The consideration payable will be subject to an arrangement providing for adjustments to the share exchange ratio where there are significant movements in the trading price of YM shares. Read more…

Viewed 2652 times by 382 viewers

• Patent for improved inhalation delivery device granted by Japan patent office
• Expands intellectual property portfolio with broad application technology for delivery of medications and substances through inhalation pathway

October 2009: Avita Medical Ltd (ASX: AVH) has been notified that the Japan Patent Office has granted the company a Japanese Patent entitled: Improved drug delivery device and methods therefore.

The patent, of broad applicability, relates to the incorporation of feedback and incentive mechanisms into devices for the improved delivery of medications and biologically active substances via the inhalation pathway.

There is a need for improved delivery devices with inhalation being the pathway of choice for many medications and biologically active substances. Read more…

Viewed 2698 times by 403 viewers

Dear Shareholder,

As you may be aware MHM has received a considerable amount of publicity recently regarding its silica project and the potential for the establishment of a large silicon smelter in Tasmania. MHM is bound by confidentiality agreements regarding any discussion on the silicon smelter proponent or any of the commercial terms. The purpose of this brief is to give a non-confidential background into this project and to provide some additional information on the Company’s other projects.

Silica Project

MHM is in negotiations with three parties who have expressed an interest in the company’s silica areas. Read more…

Viewed 2250 times by 344 viewers